Dr. Anosh Ahmed announces an expansion of his COVID-19 testing services, with new COVID testing contracts now secured and ...

At the event, physician key opinion leaders will discuss the company’s current indications in neurology and psychiatry. Members of the Axsome management team will provide an overview of the clinical ...

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today ...

YIV-906 increases safety and reduces non-hematological toxicities by cytoprotecting the gastrointestinal tract by reducing GI inflammation (NF-kB, COX2, iNOS, IL-6), promoting damaged tissue repair ...

MPS-I is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme resulting in the accumulation of glycosaminoglycans (GAGs) in multiple ...

TNX-801 is well tolerated in immunocompromised animals, without evidence of spreading to blood or tissues even at high doses ...

The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic ® network, closed the sale of 31 corporate owned and managed clinics and associated ...

Ingelheim, Germany, July 7, 2025 – Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study ( NCT06962839 ). It will investigate the efficacy, safety and tolerability of ...

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective non-hormonal contraception during treatment with AUGTYRO and for 2 months following ...

RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head ...

LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access ...

TORONTO, July 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc.